Next Article in Journal
Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing
Next Article in Special Issue
MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature
Previous Article in Journal
Living Cell Microarrays: An Overview of Concepts
Previous Article in Special Issue
Stromal Activation by Tumor Cells: An in Vitro Study in Breast Cancer
Please note that, as of 18 July 2017, Microarrays has been renamed to High-Throughput and is now published here.
Open AccessArticle

Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks

1
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA
2
Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI 48824, USA
3
University of Michigan Microarray Core, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
4
Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI 48109, USA
*
Author to whom correspondence should be addressed.
Current address: Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Research Foundation, Cincinnati, OH 45229, USA.
Academic Editor: Massimo Negrini
Microarrays 2016, 5(2), 13; https://doi.org/10.3390/microarrays5020013
Received: 30 March 2016 / Accepted: 16 May 2016 / Published: 28 May 2016
(This article belongs to the Special Issue Diagnostic, Prognostic and Predictive Cancer Biomarkers)
Metastasis is the major cause of cancer deaths and control of gene transcription has emerged as a critical contributing factor. RhoA- and RhoC-induced gene transcription via the actin-regulated transcriptional co-activator megakaryocytic leukemia (MKL) and serum response factor (SRF) drive metastasis in breast cancer and melanoma. We recently identified a compound, CCG-1423, which blocks Rho/MKL/SRF-mediated transcription and inhibits PC-3 prostate cancer cell invasion. Here, we undertook a genome-wide expression study in PC-3 cells to explore the mechanism and function of this compound. There was significant overlap in the genes modulated by CCG-1423 and Latrunculin B (Lat B), which blocks the Rho/MKL/SRF pathway by preventing actin polymerization. In contrast, the general transcription inhibitor 5,6-dichloro-1-β-d-ribofuranosyl-1H-benzimidazole (DRB) showed a markedly different pattern. Effects of CCG-1423 and Lat B on gene expression correlated with literature studies of MKL knock-down. Gene sets involved in DNA synthesis and repair, G1/S transition, and apoptosis were modulated by CCG-1423. It also upregulated genes involved in endoplasmic reticulum stress. Targets of the known Rho target transcription factor family E2F and genes related to melanoma progression and metastasis were strongly suppressed by CCG-1423. These results confirm the ability of our compound to inhibit expression of numerous Rho/MKL-dependent genes and show effects on stress pathways as well. This suggests a novel approach to targeting aggressive cancers and metastasis. View Full-Text
Keywords: metastasis; transcription; cell cycle; Rho metastasis; transcription; cell cycle; Rho
Show Figures

Figure 1

MDPI and ACS Style

Evelyn, C.R.; Lisabeth, E.M.; Wade, S.M.; Haak, A.J.; Johnson, C.N.; Lawlor, E.R.; Neubig, R.R. Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks. Microarrays 2016, 5, 13.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop